Improving Outcomes in Anaplastic Lymphocyte Kinase-Positive Metastatic Non-Small Cell Lung Cancer
Cancer Therapy Advisor,
By Clinical Content Hub Among cancer types, lung cancer is the most frequently diagnosed, having accounted for 11.4% of the…
By Clinical Content Hub Among cancer types, lung cancer is the most frequently diagnosed, having accounted for 11.4% of the…
ALK TKIs have proven efficacy in the frontline treatment of patients with advanced, ALK -positive non–small cell lung cancer (NSC…
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with…
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with…
Alice T. Shaw, MD Significantly higher response rates were seen in patients with ALK-positive non–small cell lung cancer (NSCLC…
medwireNews : Lorlatinib is more efficacious against non-small-cell lung cancer (NSCLC) with versus without ALK resistance…
In a study reported in the Journal of Clinical Oncology, Shaw et al found that lorlatinib showed greater efficacy in patients…
D. Ross Camidge, MD, PhD, and Kurtis D. Davies, PhD Journal of Clinical Oncology This Reading Room is a collaboration between…